Across U.S. workplaces, GLP-1 medications like Ozempic, Wegovy, and Mounjaro are transforming conversations around health, weight, and productivity. At the same time, they’re creating an unexpected challenge: equity.
A recent Lifesum survey of 2,000 employees found that 74% believe workplace provision of GLP-1s could widen health inequalities, while only 21% think it could help level the playing field.
